Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase

• Published in: Diabetologia Vol. 45; no. 5; pp. 668 - 676
• Main Authors: JUN, H.-S, CHUNG, Y.-H, HAN, J, KIM, A, YOO, S. S, SHERWIN, R. S, YOON, J.-W
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.05.2002
• Subjects: Adoptive Transfer - methods; Animals; Base Sequence; Biological and medical sciences; Diabetes Mellitus, Type 1 - prevention & control; Diabetes. Impaired glucose tolerance; DNA Primers; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Genetic Therapy; Genetic Vectors; Glutamate Decarboxylase - immunology; Hypoxanthine Phosphoribosyltransferase - genetics; Isoenzymes - immunology; Lymphocytes - immunology; Medical sciences; Mice; Mice, Inbred NOD; Recombination, Genetic; Spleen - immunology; Vaccines, DNA - therapeutic use; Vaccinia virus; Endocrinopathy; Animal model; Recombinant virus; Autoimmune disease; Lyases; Prevention; Carboxy-lyases; Immunopathology; Chordopoxvirinae; Immune response; Enzyme; Orthopoxvirus; Rodentia; Glutamate decarboxylase; Virus; Vaccinia virus; Carbon-carbon lyases; Vertebrata; Mammalia; Mouse; Poxviridae; Excitatory aminoacid; Neurotransmitter; Insulin dependent diabetes; Gene therapy

Type I (insulin-dependent) diabetes mellitus results from T-cell-mediated autoimmune destruction of pancreatic beta cells. Among the beta-cell autoantigens that have been implicated in triggering of beta-cell-specific autoimmunity, glutamic acid decarboxylase (GAD) is a strong candidate in both huma...